Pleiotropic Signal Transduction Mediated by Human CD30: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family

CD30, a member of the tumor necrosis factor receptor (TNFR) family, is a characteristic cell surface receptor for activated T-cells and the malignant cells of Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and a few other non-Hodgkin's lymphomas. As an independent predictor of disease progression and poor prognosis, high serum levels of soluble CD30 (sCD30) have prognostic significance for patients with CD30-positive lymphomas and viral infections. Activation of CD30 by ligand binding or cross-linking with immobilized antibody leads to trimerization of the receptor, recruitment of signaling proteins and transducing of numerous effects. Due to the lack of an intrinsic enzymatic domain, signal transduction is exclusively mediated by the members of the TNFR-associated factor (TRAF) family and the various TRAF-binding proteins. CD30 signaling can induce several pathways including the activation of NF κ B and the MAP kinases. CD30 mediated signal transduction is capable of promoting cell proliferation and cell survival as well as antiproliferative effects and cell death depending on cell type and co-stimulatory effects. Some data indicate the opposite signaling of CD30 in HD or ALCL cells, while other information point to pleiotropic signaling pathways in both malignancies. The pro and contra of this controversy is discussed in this review.

[1]  S. Morris,et al.  Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non‐hodgkin's lymphoma , 2001, British journal of haematology.

[2]  F. Carlotti,et al.  Ras controls tumor necrosis factor receptor-associated factor (TRAF)6-dependent induction of nuclear factor-kappa b. Selective regulation through receptor signaling components. , 2001, The Journal of biological chemistry.

[3]  E. Hildt,et al.  CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299 , 2001, Oncogene.

[4]  C. Duckett,et al.  Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. , 2000, Blood.

[5]  H. Lemke,et al.  CD30 Shedding from Karpas 299 Lymphoma Cells Is Mediated by TNF-α-Converting Enzyme1 , 2000, The Journal of Immunology.

[6]  S. Pileri,et al.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.

[7]  A. Winoto,et al.  The TNF Receptor Family Member CD30 Is Not Essential for Negative Selection1 , 2000, The Journal of Immunology.

[8]  A. Scheynius,et al.  Crosslinking of CD30 on Activated Human Th Clones Enhances Their Cytokine Production and Downregulates the CD30 Expression , 2000, Scandinavian journal of immunology.

[9]  T. Watts,et al.  Role of TNF Receptor-Associated Factor 2 and p38 Mitogen-Activated Protein Kinase Activation During 4-1BB-Dependent Immune Response1 , 2000, The Journal of Immunology.

[10]  M. Kadin,et al.  Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. , 2000, The Journal of investigative dermatology.

[11]  L. Boise,et al.  CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis1 , 2000, The Journal of Immunology.

[12]  H. Stein,et al.  The restricted expression pattern of the Hodgkin's lymphoma‐associated cytokine receptor CD30 is regulated by a minimal promoter , 2000, The Journal of pathology.

[13]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[14]  N. Katoh,et al.  Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26 , 2000, Clinical and experimental immunology.

[15]  J. Inoue,et al.  TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.

[16]  S. Hsu,et al.  Autocrine Growth Regulation of CD30 Ligand in CD30-Expressing Reed-Sternberg Cells: Distinction Between Hodgkin's Disease and Anaplastic Large Cell Lymphoma , 2000, Laboratory Investigation.

[17]  P. Vandenabeele,et al.  TTRAP, a Novel Protein That Associates with CD40, Tumor Necrosis Factor (TNF) Receptor-75 and TNF Receptor-associated Factors (TRAFs), and That Inhibits Nuclear Factor-κB Activation* , 2000, The Journal of Biological Chemistry.

[18]  F. Foschi,et al.  Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity? , 2000, Cytokine.

[19]  C. Meijer,et al.  ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination , 2000, Journal of clinical pathology.

[20]  A. Gout,et al.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. , 2000, The American journal of pathology.

[21]  S. Pileri,et al.  Expression of the CD30 antigen in non‐lymphoid tissues and cells , 2000, The Journal of pathology.

[22]  M. Fujimoto,et al.  Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. , 2000, The Journal of rheumatology.

[23]  G. Cheng,et al.  Membrane Localization of TRAF 3 Enables JNK Activation* , 2000, The Journal of Biological Chemistry.

[24]  S. Nomura,et al.  Serum levels of soluble CD30 in autologous peripheral blood stem cell transplantation , 2000, Journal of Cancer Research and Clinical Oncology.

[25]  H. Lemke,et al.  CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. , 2000, Journal of immunology.

[26]  D. Baltimore,et al.  NF‐κB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK‐related kinase , 1999, The EMBO journal.

[27]  I. Scheffrahn,et al.  The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. , 1999, Experimental hematology.

[28]  C. Pitzalis,et al.  Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. , 1999, Rheumatology.

[29]  B. Giannotti,et al.  CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. , 1999, Blood.

[30]  R. Beyaert,et al.  TRAF1 is a TNF inducible regulator of NF‐κB activation , 1999 .

[31]  Zhengbin Yao,et al.  Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1) , 1999, Oncogene.

[32]  M. Kadin,et al.  A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). , 1999, The American journal of pathology.

[33]  T. Alber,et al.  High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. , 1999, Biochemistry.

[34]  R. Warnke,et al.  CD30 expression is common in mediastinal large B-cell lymphoma. , 1999, American journal of clinical pathology.

[35]  Peter Scheurich,et al.  The Human Tumor Necrosis Factor (TNF) Receptor-associated Factor 1 Gene (TRAF1) Is Up-regulated by Cytokines of the TNF Ligand Family and Modulates TNF-induced Activation of NF-κB and c-Jun N-terminal Kinase* , 1999, The Journal of Biological Chemistry.

[36]  G. Inghirami,et al.  CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. , 1999, Journal of immunology.

[37]  Peter Scheurich,et al.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.

[38]  S. Pileri,et al.  ALK+ lymphoma: clinico-pathological findings and outcome. , 1999, Blood.

[39]  Hao Wu,et al.  Structural basis for self-association and receptor recognition of human TRAF2 , 1999, Nature.

[40]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[41]  B. Aggarwal,et al.  Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.

[42]  J. Inoue,et al.  Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Baltimore,et al.  Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Inghirami,et al.  CD30 in normal and neoplastic cells. , 1999, Clinical immunology.

[45]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[46]  N. Tanaka,et al.  Circulating levels of soluble CD30 and other markers in colorectal cancer patients. , 1999, Journal of medicine.

[47]  R. Beyaert,et al.  TRAF1 is a TNF inducible regulator of NF-kappaB activation. , 1999, FEBS letters.

[48]  E. Reddy,et al.  Modulation of life and death by the TNF receptor superfamily , 1998, Oncogene.

[49]  S. Morris,et al.  Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity , 1998, Molecular and Cellular Biology.

[50]  Soo Young Lee,et al.  Stimulus-dependent Synergism of the Antiapoptotic Tumor Necrosis Factor Receptor–associated Factor 2 (TRAF2) and Nuclear Factor κB Pathways , 1998, The Journal of experimental medicine.

[51]  C. Thompson,et al.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. , 1998, Genes & development.

[52]  P. Lipsky,et al.  TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. , 1998, Journal of immunology.

[53]  P. Casali,et al.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. , 1998, Immunity.

[54]  V. Dixit,et al.  RIP2 Is a Novel NF-κB-activating and Cell Death-inducing Kinase* , 1998, The Journal of Biological Chemistry.

[55]  M. Chilosi,et al.  Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. , 1998, Blood.

[56]  S. Pileri,et al.  Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Tschopp,et al.  Herpesvirus Saimiri Transforms Human T-Cell Clones to Stable Growth without Inducing Resistance to Apoptosis , 1998, Journal of Virology.

[58]  H. Nakano,et al.  Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1 , 1998 .

[59]  Zhaodan Cao,et al.  NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176 , 1998 .

[60]  Takashi Uchiyama,et al.  Activation of OX40 Signal Transduction Pathways Leads to Tumor Necrosis Factor Receptor-associated Factor (TRAF) 2- and TRAF5-mediated NF-κB Activation* , 1998, The Journal of Biological Chemistry.

[61]  J. Inoue,et al.  A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. , 1998, International immunology.

[62]  K. Okazaki,et al.  Tumor Necrosis Factor Receptor–associated Factor 6 (TRAF6) Stimulates Extracellular Signal–regulated Kinase (ERK) Activity in CD40 Signaling Along a Ras-independent Pathway , 1998, The Journal of experimental medicine.

[63]  D. Goeddel,et al.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Nakano,et al.  Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  V. Dixit,et al.  RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. , 1998, The Journal of biological chemistry.

[66]  W. Telford,et al.  CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. , 1997, Cellular immunology.

[67]  C. Thompson,et al.  CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. , 1997, Genes & development.

[68]  K. Kliche,et al.  CD30 ligand in lymphoma patients with CD30+ tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Mike Rothe,et al.  IκB Kinase-β: NF-κB Activation and Complex Formation with IκB Kinase-α and NIK , 1997 .

[70]  D. Goeddel,et al.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. , 1997, Science.

[71]  H. Stein,et al.  Expression of several members of the TNF‐ligand and receptor family on tonsillar lymphoid B cells , 1997, British journal of haematology.

[72]  E. Bröcker,et al.  Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis , 1997, The British journal of dermatology.

[73]  G. Ishii,et al.  12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562 , 1997, Hematological oncology.

[74]  I. Zaki,et al.  Graft‐versus‐host disease‐like eruption in a patient with non‐Hodgkin's lymphoma , 1997, The British journal of dermatology.

[75]  M. Chilosi,et al.  High serum level of soluble CD30 in acute primary HIV‐1 infection , 1997, Clinical and experimental immunology.

[76]  T. Mak,et al.  Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. , 1997, Biochemical and biophysical research communications.

[77]  G. Chiappetta,et al.  Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. , 1997, Blood.

[78]  Soo-Young Lee,et al.  TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-κB Activation , 1997, The Journal of experimental medicine.

[79]  M. Di Franco,et al.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease , 1997, Clinical and experimental immunology.

[80]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[81]  C. Thompson,et al.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2 , 1997, Molecular and cellular biology.

[82]  L. Williams,et al.  Tumor necrosis factor α‐induced activation of c‐jun N‐terminal kinase is mediated by TRAF2 , 1997, The EMBO journal.

[83]  R. Geha,et al.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[85]  Ko Okumura,et al.  Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-mediated NFκB Activation* , 1997, The Journal of Biological Chemistry.

[86]  G. Natoli,et al.  Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway , 1997, Science.

[87]  D. Weisenburger,et al.  Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. , 1997, Blood.

[88]  G. Pantaleo,et al.  Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: relationship with HIV-1, RNA, clinical outcome and early antiviral therapy. , 1997, Journal of Biological Regulators and Homeostatic Agents.

[89]  E. Kieff,et al.  Identification of TRAF6, a Novel Tumor Necrosis Factor Receptor-associated Factor Protein That Mediates Signaling from an Amino-terminal Domain of the CD40 Cytoplasmic Region* , 1996, The Journal of Biological Chemistry.

[90]  E. Kieff,et al.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Lee,et al.  CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[92]  D. Goeddel,et al.  The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Andreeff,et al.  CD30 ligand is expressed on resting normal and malignant human B lymphocytes , 1996, British journal of haematology.

[94]  C. Thompson,et al.  CD30 Contains Two Binding Sites with Different Specificities for Members of the Tumor Necrosis Factor Receptor-associated Factor Family of Signal Transducing Proteins* , 1996, The Journal of Biological Chemistry.

[95]  D. Vaux,et al.  Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  H. Griesser,et al.  Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice , 1996, Cell.

[97]  M. Jäättelä,et al.  A20 zinc finger protein inhibits TNF and IL-1 signaling. , 1996, Journal of immunology.

[98]  Soo-Young Lee,et al.  T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors , 1996, The Journal of experimental medicine.

[99]  E. Reddy,et al.  Transducers of life and death: TNF receptor superfamily and associated proteins. , 1996, Oncogene.

[100]  G. Fattovich,et al.  Serum levels of soluble CD30 in chronic hepatitis B virus infection , 1996, Clinical and experimental immunology.

[101]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[102]  B. Falini,et al.  High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints , 1995, Clinical and experimental immunology.

[103]  A. Scheynius,et al.  Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation , 1995, Journal of leukocyte biology.

[104]  J. Kobarg,et al.  A zinc metalloproteinase is responsible for the release of cd30 on human tumor cell lines , 1995, International journal of cancer.

[105]  D. Longo,et al.  In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. , 1995, Cancer research.

[106]  G. Pizzolo,et al.  CD30 ligation induces nuclear factor‐ϰB activation in human T cell lines , 1995, European journal of immunology.

[107]  D. Goeddel,et al.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.

[108]  H. Stein,et al.  Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[110]  H. Stein,et al.  CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. , 1995, The American journal of pathology.

[111]  K. Muir,et al.  Immunophenotypic analysis of childhood Burkitt's lymphoma in the West Midlands 1957-1986. , 1995, Journal of clinical pathology.

[112]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[113]  F. Stirpe,et al.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. , 1995, Blood.

[114]  M. Pfreundschuh,et al.  Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. , 1994, Molecular immunology.

[115]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[116]  D. Goeddel,et al.  A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor , 1994, Cell.

[117]  H. Satoh,et al.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.

[118]  H. Stein,et al.  High serum level of the soluble form of CD30 molecule in the early phase of HIV‐1 infection as an independent predictor of progression to AIDS , 1994, AIDS.

[119]  R. Armitage.  Tumor necrosis factor receptor superfamily members and their ligands. , 1994, Current opinion in immunology.

[120]  G. Nadali,et al.  Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[122]  L. Tartaglia,et al.  A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.

[123]  R. Fisher,et al.  CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. , 1993, Journal of immunology.

[124]  N. Copeland,et al.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF , 1993, Cell.

[125]  H. Stein,et al.  Assignment of the human CD30 (Ki-1) gene to 1p36. , 1992, Genomics.

[126]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[127]  V. Diehl,et al.  Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. , 1991, Blood.

[128]  G. Pallesen.  The diagnostic significance of the CD30 (Ki‐1) antigen , 1990, Histopathology.

[129]  S. Pileri,et al.  BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. , 1989, Blood.

[130]  H. Stein,et al.  Ki‐1 (CD30) antigen is released by Ki‐1‐positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki‐1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme‐linked immunosorbent assay , 1989, European journal of immunology.

[131]  S. Hamilton-Dutoit,et al.  Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. , 1988, The American journal of pathology.

[132]  R. Fisher,et al.  Biochemical and structural properties of a Hodgkin's disease-related membrane protein. , 1988, Journal of immunology.

[133]  H. Stein,et al.  Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. , 1987, Journal of immunology.

[134]  H. Stein,et al.  High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. , 1986, Journal of clinical pathology.

[135]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[136]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.